Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes
- PMID: 9631245
- DOI: 10.1007/BF02737835
Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes
Abstract
Lipopolysaccharide (LPS)-induced liver injury in mice and LPS-induced tumor necrosis factor-alpha (TNF-alpha) generation by murine macrophages and hepatocytes are suppressed markedly by agents that elevate intracellular cAMP. Phosphodiesterase (PDE)-4 inhibitors, beta 2-adrenoceptor agonists, and E-series prostaglandins also attenuate the induction of the TNF-alpha gene in human monocytes in response to bacterial LPS. The mechanism of action of cAMP is unclear, but in the mouse, is believed to involve the generation of this anti-inflammatory cytokine, interleukin-10 (IL-10). In this article, we describe the results of studies designed to determine the extent to which IL-10 contributes to the suppression of TNF-alpha generation from LPS-stimulated human monocytes evoked by 8-bromo cyclic AMP (8-Br-cAMP), rolipram, salbutamol, and prostaglandin E2 (PGE2). LPS evoked a time- and concentration-dependent generation of TNF-alpha (t1/2 = 4.5 h; EC50 = 273 pg/mL), which was inhibited by exogenous human recombinant (h) IL-10 (IC50 = 124 pg/mL), and by rolipram (EC50 = 420 nM), 8-Br-cAMP (EC50 = 77 (microM), PGE2 (EC50 = 15 nM) and salbutamol (EC50 = 20 nM). In addition, 8-Br-cAMP, PGE2; and salbutamol (but not rolipram) augmented significantly LPS-induced IL-10 production (two-to-fivefold) under identical experimental conditions. Pretreatment of monocytes with an anti-IL-10 monoclonal antibody (MAb) that abolished the inhibitory action of a maximally effective concentration of exogenous hrIL-10, failed to attenuate the inhibitory effect of rolipram, PGE2, salbutamol, and 8-Br-cAMP. Anti-IL-10 was similarly inactive when the number of monocytes seeded was increased from 0.5 to 4 x 10(6)/mL or when measurements were made at 42 h post-LPS, a time when the concentration of IL-10 released was maximal. Collectively, these data suggest that in contrast to murine hepatocytes and macrophages, IL-10 does not mediate the inhibitory effect of cAMP-elevating drugs on TNF-alpha generation from human monocytes. Although the reason for this discrepancy is unclear, we suggest that the influence of cAMP on the transcriptional regulation of the TNF-alpha gene differs between species or when monocytes have differentiated into macrophages.
Similar articles
-
Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.Mol Pharmacol. 1995 Oct;48(4):747-57. Mol Pharmacol. 1995. PMID: 7476903
-
In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors.Br J Pharmacol. 1997 May;121(2):221-31. doi: 10.1038/sj.bjp.0701124. Br J Pharmacol. 1997. PMID: 9154331 Free PMC article.
-
Suppression of granulocyte/macrophage colony-stimulating factor release from human monocytes by cyclic AMP-elevating drugs: role of interleukin-10.Br J Pharmacol. 2001 Sep;134(1):58-67. doi: 10.1038/sj.bjp.0704238. Br J Pharmacol. 2001. PMID: 11522597 Free PMC article.
-
Causes of the urinary concentrating defect in mice with nephrogenic diabetes insipidus.Physiol Bohemoslov. 1990;39(1):103-11. Physiol Bohemoslov. 1990. PMID: 2165265 Review.
-
[Modulation of cytokine production from human mononuclear cells by several agents].Yakugaku Zasshi. 2000 Dec;120(12):1277-90. doi: 10.1248/yakushi1947.120.12_1277. Yakugaku Zasshi. 2000. PMID: 11193379 Review. Japanese.
Cited by
-
Differential inhibitory mechanism of cyclic AMP on TNF-alpha and IL-12 synthesis by macrophages exposed to microbial stimuli.Br J Pharmacol. 1999 Jul;127(5):1195-205. doi: 10.1038/sj.bjp.0702624. Br J Pharmacol. 1999. PMID: 10455266 Free PMC article.
-
Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.Br J Pharmacol. 2010 Feb;159(4):842-55. doi: 10.1111/j.1476-5381.2009.00559.x. Epub 2009 Dec 24. Br J Pharmacol. 2010. PMID: 20050849 Free PMC article.
-
Impaired host defense to Klebsiella pneumoniae infection in mice treated with the PDE4 inhibitor rolipram.Br J Pharmacol. 2003 Nov;140(5):855-62. doi: 10.1038/sj.bjp.0705517. Br J Pharmacol. 2003. PMID: 14585803 Free PMC article.
-
Influence of phthalates on in vitro innate and adaptive immune responses.PLoS One. 2015 Jun 25;10(6):e0131168. doi: 10.1371/journal.pone.0131168. eCollection 2015. PLoS One. 2015. PMID: 26110840 Free PMC article.
-
The modulatory effects of prostaglandin-E on cytokine production by human peripheral blood mononuclear cells are independent of the prostaglandin subtype.Immunology. 2002 Sep;107(1):152-9. doi: 10.1046/j.1365-2567.2002.01474.x. Immunology. 2002. PMID: 12225374 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources